Papillary renal cell carcinoma: Clinical implication of DNA content analysis

El‐Naggar, Adel K.; Ro, Jae Y.; Ensign, Lisa G.

doi:10.1016/0046-8177(93)90043-g

Cited by 28 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings suggest that patients with Type 2 tumors should benefit from a more strict follow-up. In our series, the TNM stage was not significantly associated with prognosis, but we observed, like other authors, that the Fuhrman grade remains a valuable prognostic factor of papillary renal cell carcinomas (10,12,14).…”

Section: Discussionmentioning

confidence: 47%

Morphologic Subtyping of Papillary Renal Cell Carcinoma: Correlation with Prognosis and Differential Expression of MUC1 between the Two Subtypes

et al. 2002

View full text Add to dashboard Cite

Papillary renal cell carcinoma is the second most frequent malignant neoplasm of the adult kidney. It accounts for 10 -15% of all renal carcinomas (1). Papillary renal cell carcinoma is now a wellestablished entity with specific morphological, immunohistochemical, and cytogenetic features. Classical prognostic factors used for renal carcinomas are the TNM stage and the Fuhrman grade. Usually, papillary renal cell carcinoma has been considered to have a better prognosis than clear renal cell carcinoma (1-2). Delahunt and Eble (3) have proposed to divide papillary renal cell carcinomas in two morphological types. Type 1 tumor is characterized by small cuboidal cells covering thin papillae with a single line of uniform nuclei and small nucleoli. In Type 2 tumors, the papillae are covered by large eosinophilic cells with pleomorphic nuclei, prominent nucleoli, and nuclear pseudostratification (3). Recently studying a series of 66 cases, Delahunt et al. (4) showed that this morphologic subtyping is an independent predictive factor of outcome. Indeed, Type 2 was associated with a significantly higher Fuhrman grade and a poorer prognosis (4). MUC1 is a large transmembrane glycoprotein expressed in many normal and tumor epithelial cells. MUC1 is frequently overexpressed in carcinoma and is associated with tumor progression and poorer prognosis (5-6). In clear renal cell carcinoma, MUC1 is overexpressed, and the level of expression is associated with the Fuhrman grade and with the tumor progression (7-9).The current study was performed to investigate the prognostic value of histologic typing in papillary renal cell carcinoma and to evaluate the expression of MUC1 in the two types.

show abstract

Section: Discussionmentioning

confidence: 47%

Morphologic Subtyping of Papillary Renal Cell Carcinoma: Correlation with Prognosis and Differential Expression of MUC1 between the Two Subtypes

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Among renal tumors papillary renal cell carcinoma (PRCC) is a well-recognized, distinct (supported by genetic studies) tumor type [2,7,[9][10][11][12]. Delahunt and Eble have recently proposed the existence of two different subtypes of PRCC [7].…”

Section: Discussionmentioning

confidence: 99%

Papillary renal cell carcinoma: clinicopathological characteristics in 40 patients

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Papillary renal cell carcinoma is a well-recognized distinct tumor type among renal tumors, even though this group exhibits a large range of morphological variants [1,4,6,8,18,20,22,24,25,26,27]. Delahunt and Eble [6] have recently proposed a subtyping of PRCC into two morphological subtypes: type 1 (small cells with scanty cytoplasm arranged in a single or double layer), and type 2 (cells with voluminous and usually eosinophilic cytoplasm, arranged in a pseudo-or irregularly stratified manner), which could be associated with a favorable or a pejorative prognosis, respectively [6].…”

Section: Discussionmentioning

confidence: 99%

“…In the revised classification of renal cell neoplasia [15,30], papillary renal cell carcinoma (PRCC) is recognized as a distinct tumor type, supported by multiple morphological [1,4,8,18,20,22,24], immunohistochemical [10,24], and genetic [5,12,13,14,16] studies. PRCCs represent approximately 15-20% of renal epithelial tumors [3,18,20] and are typically characterized by a predominant papillary pattern (more than 50% at least of the tumor) [1,18,24], a cytokeratin 7-positive immunophenotype [10], and recurrent cytogenetic alterations consistently showing trisomy or tetrasomy of chromosomes 7 and 17, and with a high-frequency loss of chromosome Y, trisomies 12, 16, and 20 [5,12,13,14,16].…”

Section: Introductionmentioning

confidence: 99%

“…However, large and recent studies, taking into account the stage and the nuclear grade, have revealed a similar prognosis for PRCC in comparison with CRCC [19,21]. Indeed, various architectural variants-including trabecular, tubular, solid, and collecting duct-like patterns-and cytological subtypes-basophilic, eosinophilic, or clear cell-have been described [1,8,18,22,23,24,25,26,27,31], and 20% of PRCCs at least have been reported lacking the typical trisomy 17 [5,11,13,14]. Indeed, various architectural variants-including trabecular, tubular, solid, and collecting duct-like patterns-and cytological subtypes-basophilic, eosinophilic, or clear cell-have been described [1,8,18,22,23,24,25,26,27,31], and 20% of PRCCs at least have been reported lacking the typical trisomy 17 [5,11,13,14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Papillary renal cell carcinoma

et al. 2003

View full text Add to dashboard Cite

A series of 43 papillary renal cell carcinomas (PRCCs) were analyzed to investigate the prognostic value of the morphological subtyping (type 1/type 2) proposed by Delahunt and Eble [6]. Twenty-six cases were type 1 (small cuboid cells arranged in single or double layers), 13 cases were type 2 (voluminous eosinophilic cells with irregular pseudostratification pattern), and four cases with oncocytic cells (large eosinophilic cells with round regular nuclei) were distinct from type 2 and grouped apart. All type-1 and oncocytoid-type PRCCs were staged pT1 or pT2, whereas 8/13 type-2 PRCCs were staged pT3 or pT4. Follow-up information (range, 3-113 months; median, 43 months) showed 12 deaths from disease: 2 in the type-1 group,10 in the type-2 group, 0 in the oncocytoid-type group. The Kaplan-Meier analysis showed that pejorative outcome was associated (P<0.001) with high stage (pT3/pT4), high nuclear grade (3/4), morphological type 2, absence of foam cells, and abundant fibrous stroma. The multivariate analysis showed that stage and morphological type were independently associated with survival (P<0.05). These results support the clinical interest of morphological subtyping of PRCCs in the prognosis evaluation of the patients. The four oncocytoid-type PRCCs had a favorable outcome, but additional data are required to evaluate this type of neoplasm.

show abstract

Papillary renal cell carcinoma: Clinical implication of DNA content analysis

Cited by 28 publications

References 23 publications

Morphologic Subtyping of Papillary Renal Cell Carcinoma: Correlation with Prognosis and Differential Expression of MUC1 between the Two Subtypes

Morphologic Subtyping of Papillary Renal Cell Carcinoma: Correlation with Prognosis and Differential Expression of MUC1 between the Two Subtypes

Papillary renal cell carcinoma: clinicopathological characteristics in 40 patients

Papillary renal cell carcinoma

Contact Info

Product

Resources

About